-
Views
-
Cite
Cite
Ian Hennessee, Kaitlin Benedict, Nathan C Bahr, Shari R Lipner, Jeremy A W Gold, Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor–Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis, Clinical Infectious Diseases, Volume 80, Issue 2, 15 February 2025, Pages 364–366, https://doi.org/10.1093/cid/ciae444
- Share Icon Share
Abstract
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor–alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.

This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/incidence-and-risk-factors-for-invasive-fungal-infections-in-patients-initiating-tnf-alpha-inhibitors-for-inflammatory-bowel-disease-and-rheumatoid-arthritis-c90b04e8-ca6c-4426-91f5-914665e57f70?utm_campaign=tidbitlinkshare&utm_source=IO